An update on the use of Atripla® in the treatment of HIV in the United States

Abstract

Atripla(®) (Gilead Sciences Inc, Foster City, CA, USA and Bristol-Myers Squibb, New York City, NY, USA) is a coformulated single pill composed of efavirenz, emtricitabine, and tenofovir disoproxil, intended as a once-daily potent combination antiretroviral therapeutic agent. Its efficacy is equivalent to the 3 component drugs taken in a combination as… (More)

Topics

Cite this paper

@inproceedings{Horberg2010AnUO, title={An update on the use of Atripla® in the treatment of HIV in the United States}, author={Michael A Horberg and Daniel Benjamin Klein}, booktitle={HIV/AIDS}, year={2010} }